Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease

Annals of Oncology

Volumn 10, Issue 3, 1999, Pages 311-316

  Coleman, R E ^a   Purohit, O P ^a   Black, C ^a   Vinholes, J J F ^a   Schlosser, K ^b,c   Huss, H ^b,c   Quinn, K J ^b,c   Kanis, J ^d  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b Boehringer Mannheim Therapeutics   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Bone resorption markers; Ibandronate; Metastatic bone disease

Indexed keywords

IBANDRONIC ACID;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENCY; DRUG TOLERANCE; DYSPHAGIA; ESOPHAGUS ULCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0032956195     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008386501738     Document Type: Article

References (29)

1. Body JJ, Borkowski A, Cleeren A, Bijvoet OLM. Treatment of malignancy-associated hypercalcemia with intravenous amino-hydroxypropylidene diphosphonate (APD). J Clin Oncol 1986; 4: 1177-83.
2. O'Rourke NP, McCloskey EV, Vasikaran S et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67: 560-3.
3. Purohit OP, Radstone CR, Anthony C et al. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer 1995; 72: 1289-93.
4. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 1996; 335: 1785-91.
5. Lipton A, Theriault R, Leff R et al. Long-term reduction of skelelal complications in breast cancer patients with osteolytic bone metastases receiving hormone therapy, by monthly 90 mg pamidronate (Aredia™) infusions. Proc ASCO 1997; 16: 152a.
6. Patterson AHG, Powles TJ, Kanis JA et al. Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer. J Clin Oncol 1993; 11: 59-65.
7. Lahtinen R, Laakso M, Palva I et al. for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52.
8. McCloskey EV, Maclennan ICM, Drayson M et al. A randomised trial of the effect of clodronate on skeletal morbidity in multiple myeloma. Br J Haematol 1998; 100: 317-25.
9. Berenson JR, Lichtenstein A, Porter L et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
10. Coleman RE, Houston S, Purohit OP et al. A randomised phase II evaluation of oral pamidronate for advanced bone metastases from breast cancer. Eur J Cancer 1998; 34: 820-4.
11. De Groen PC, Lubbe DF, Hirsch LJ et al. Oesophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-21.
12. Muhlbauer RC, Bauss F, Schenk R et al. BM21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 1991; 6: 1003-11.
13. Bauss F, Muhlbauer RC. Ibandronate, monosodium salt, monohydrate. Drugs Future 1994; 19: 13-6.
14. Vinholes JJ, Guo C-Y, Purohit OP et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996; 73: 1089-95.
15. Vinholes J, Guo C-Y, Purohit OP et al. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcaemia of malignancy. J Clin Oncol 1997; 15: 131-8.
16. Siebel MJ, Robins SP, Bilezikian JP. Urinary pyridinium cross-links of collagen. Specific marker of bone resorption in metabolic bone disease. Trends Endocrinol Metab 1992; 3; 263-70.
17. Hanson D, Weis MAE, Bollen AM et al. A specific immunoassay for monitoring human bone resoption: Quantification of type 1 collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251-8.
18. Bonde M, Qvist P, Chriastensen C et al. Applications of an enzyme immunoassay for a new marker of bone resorption (Crosslaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 864-8.
19. Rosenquist C, Bonde M, Fledulus C, Qvist P. A simple enzyme-linked immuno-adsorbent assay of human osteocalcin. Clin Chem 1994; 40: 1258-64.
20. Melkko J, Niemi S, Risteli J. Radioimmunoassay of the carboxy-terminal propeptide of human type 1 procollagen. Clin Chem 1990; 36: 1328-32.
21. Coleman RE, Whitaker KD, Moss DW et al. Biochemical monitoring predicts response in bone to systemic treatment. Br J Cancer 1988; 58: 205-10.
22. Vinholes J, Coleman R, Eastell R. Effects of bone metastases on bone metabolism: Implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996; 22: 289-331.
23. Garnero P, Christiansen C, Delmas P et al. Different effects of bisphosphonate and oestrogen therapy on free and peptide bound cross-links excretion. J Bone Miner Res 1995; 10: 641-9.
24. Vinholes JJ, Purohit OP, Abbey ME et al. Relationships between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol 1997; 8: 1243-50.
25. Coleman RE. Biochemical markers of malignant bone disease. In Rubens RD, Mundy GR (eds): Cancer and the Skeleton. London: Martin Dunitz 1999 (in press).
26. Ernst DS, MacDonald RN, Paterson AHG et al. A double-blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Symp Manage 1992; 7: 4-11.
27. Body JJ. Clinical research update: Zoledronate. Cancer 1997; 80 (8 Suppl): 1699-701.
28. Thurlimann B, Koberle D, Engler H, Bacchus L et al. Predictive factors for response to bisphosphonate treatment in malignant osteolytic bone disease: Who will respond to pamidronate? Proc ASCO 1997; 16: 52a.
29. Robertson AG, Reed NS, Ralston SH. Effect of oral clodronate on metastatic bone pain: A double-blind, placebo-controlled study. J Clin Oncol 1995; 13: 2427-30.